Navigation Links
Clexane(R)/Lovenox(R) Approved in Japan
Date:1/28/2008

risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

1. Cohen AT et al. A large-scale, global observational study of venous thromboembolism risk and prophylaxis in the acute hospital care setting: the ENDORSE study. Abstract Ndegrees 1827, International Society on Thrombosis and Haemostasis, Geneva, 8 July 2007.

2. The seventh ACCP conference on Antithrombotic and Thrombotic Therapy. Chest. 2004.

3. Cohen AT on behalf of the VTE Impact Assessment Group in Europe (VITAE). Venous Thromboembolism (VTE) in Europe: The number of VTE events and associated morbidity and mortality. Thromb
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
2. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
3. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
8. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
9. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... SEATTLE , April 30, 2015  The Paul ... Allen Distinguished Investigator (ADI) grants to six groups of ... the most challenging roadblocks in neuroscience: growing mature human ... at a total of $7.5 million over three years.  ... Investigators and their research is especially significant because the ...
(Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
(Date:4/29/2015)... April 30, 2015 According to ... Market by Product (Portable & Non-Portable), Component (Accelerometer, ... Automotive, Chemical, Metal & Mining, & Others), & ... market is expected to reach $1,453.76 Million by ... 71 market data tables and 92 figures spread ...
(Date:4/29/2015)... 2015 AlloSource ®, one of ... skin and soft-tissue allografts for use in surgical ... announced the launch of AlloSkin™ AC, an acellular ... Services (CMS) also moved AlloSkin™ RT, a meshed ... high-cost category for reimbursement. "AlloSource is ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4AlloSource Announces New Possibilities In Wound Care 2
... Dec. 21 Ipsogen SA (Alternext: ALIPS) today announced ... tumor grade in chemotherapy prescription has been presented at ... December 9-13, 2009. , The study was conducted ... Using the centre database and a classification tree method, ...
... , - Company,s results amongst the ... CITY, Dec. 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) ... affordable vaccines based on proprietary manufacturing technologies and Virus-Like ... Phase I human clinical trial with its H5N1 Avian ...
... METTLER TOLEDO recently ... FTIR Analytics as a Process Analytical Technology (PAT), on January 20, 2010. , ... (PRWEB) December 20, 2009 -- METTLER TOLEDO ... In Situ FTIR Analytics as a Process Analytical Technology (PAT), on January 20, ...
Cached Biology Technology:Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 2Medicago reports positive Phase I results for its avian flu pandemic vaccine 3Medicago reports positive Phase I results for its avian flu pandemic vaccine 4Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... animal models is enabling a deeper understanding of the ... that may lead to more effective treatment options to ... The findings were released today at Neuroscience 2009, the ... source of emerging news about brain science and health. ...
... a child,s speech development if the habit goes on ... in Patagonia, Chile, researchers associated the persistence of these ... in preschool children. The children were more likely to ... their pronunciation. The results were published Wednesday, Oct. ...
... the environmental equivalent of the ASX200 as a means of ... of an ecosystem can be understood by measuring the right ... of the Australian stock market by following 200 selected stocks. ... Hayes, one of the leaders of the project, says the ...
Cached Biology News:Studies improve knowledge of underlying brain changes caused by addiction 2Infant sucking habits may affect how baby talks 2Finding the ASX200 for marine ecosystems 2
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
... ES1301 mutS are mismatch repair minus strains ... prevents repair of the newly synthesized unmethylated ... and making them helpful in such systems ... Mutagenesis Systems. Both ES1301 and BMH 71-18 ...
Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: